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Background
Parasitaemia on day 3 has been proposed as useful alert
of potential artemisinin resistance, however, the normal
variation of parasite clearance observed in ACT clinical
trials is poorly documented. We reviewed the trends in
parasite clearance following treatment with an artemisi-
nin antimalarial regimen.
Methods
A PubMed literature search identified all studies of
uncomplicated falciparum malaria published between
January 2000 and December 2012. References were indi-
vidually reviewed to identify clinical efficacy studies.
Data from clinical studies using an artemisinin deriva-
tive were extracted and entered into a Microsoft Office
Access database for analysis.
Results
In total 65,078 patients were enrolled into 213 clinical
trials of artemisinin-containing regimens with 413 treat-
ment arms containing either an artemisinin derivative
alone (n=26) or in combination with a partner drug
(n=387). The proportion of patients remaining parasitae-
mic at 24, 48 and 72 hours was documented in 115
(28%), 167 (40%) and 153 (37%) treatment arms, respec-
tively. Excluding resistance studies in Cambodia, the
median proportion of patients still parasitaemic was
53.8% [range 3-95, IQR=30.5-69.2] at 24 hours, 6%
[range 0-65.9, IQR=2-11.5] at 48 hours and 0 [range 0-
12.6, IQR=0-2] at 72 hours. Comparing studies from
2000-2005 and 2006-2011, the median proportion of
patients remaining parasitaemic at 72 hours decreased in
Africa (1.6% vs. 0, p=0.0004), but increased in Asia (0.8%
vs. 1.2%, p=<0.0001). Overall in 95% of these studies the
proportion of patients with peripheral parasitaemia was
<6% at 72 hours.
Conclusion
These results highlight a normal range of parasite clear-
ance times that will underpin a surveillance system
based on day 3 positivity and the impact of heterogene-
ity in study design, host and parasite factors. Greater
understanding of factors influencing parasite clearance
will come from analysis of pooled data from individual
patient records.
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